title: Involvement of renal cytochromes P450 and arachidonic acid metabolites in diabetic nephropathy.
abstract: Diabetic nephropathy (DN) is one of the most serious complications of type I and type II diabetes. DN is characterized by hyperfiltration, hypertrophy, extracellular matrix accumulation, and proteinuria. This advances into renal fibrosis and loss of renal function. Reactive oxygen species (ROS) and TGF-beta have been implicated in the pathogenesis of diabetic nephropathy. Early stages of diabetic nephropathy are also associated with alterations in renal sodium handling as well as hypertension; both are processes linked by involvement of the arachidonic acid (AA) metabolites, 20-hydroxyeicosatetraenoic acid (20-HETE, produced by cytochrome P450-4a, (CYP4A) and epoxyeicosatrienoic acids (EETs). Indeed, metabolism of AA is increased in a rat model of diabetes. In this study, we demonstrate that rats with streptozotocin-induced diabetes of 1 month duration develop renal hypertrophy and increased fibronectin and TGF-beta1 expression/cortical levels concomitant with an increase in CYP4A expression and 20 HETE production. These results were also paralleled by an increase in reactive oxygen species (ROS) production and NADPH oxidase activity. Treatment of diabetic rats with HET0016, selective inhibitor of CYP 4A, prevented all these changes. Our results suggest that diabetes-induced induction of CYP4A and 20-HETE production could be a major pathophysiological mechanism leading to activation of ROS through an NADPH dependent pathway and TGF-beta1 thus resulting in major renal pathology. Inhibitors of 20-HETE production could thus have an important therapeutic potential in the treatment of diabetic nephropathy.
authors.affiliation: Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Lebanon.
authors.forename: S
authors.initials: S
authors.lastname: Eid
authors.forename: W
authors.initials: W
authors.lastname: Abou-Kheir
authors.forename: R
authors.initials: R
authors.lastname: Sabra
authors.forename: G
authors.initials: G
authors.lastname: Daoud
authors.forename: A
authors.initials: A
authors.lastname: Jaffa
authors.forename: F N
authors.initials: FN
authors.lastname: Ziyadeh
authors.forename: L
authors.initials: L
authors.lastname: Roman
authors.forename: A A
authors.initials: AA
authors.lastname: Eid
mesh_terms: D000818:Animals; D042926:Cytochrome P-450 CYP4A / Q000502:physiology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003928:Diabetic Nephropathies / Q000209:etiology*; D006893:Hydroxyeicosatetraenoic Acids / Q000502:physiology*; D007668:Kidney / Q000201:enzymology* / Q000473:pathology; D008297:Male; D019255:NADPH Oxidases / Q000378:metabolism; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D013311:Streptozocin; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis
chemical_list: D006893:Hydroxyeicosatetraenoic Acids; D017382:Reactive Oxygen Species; D053773:Transforming Growth Factor beta1; D013311:Streptozocin; C055987:20-hydroxy-5,8,11,14-eicosatetraenoic acid; D042926:Cytochrome P-450 CYP4A; D019255:NADPH Oxidases